An open study of methylphenidate in bipolar depression
1Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, KY 40292, USA. rselma01@athena.louisville.edu
Bipolar Disorders
|March 20, 2001
Summary
Methylphenidate shows promise for treating bipolar depression when added to mood stabilizers. This open study found it effective and relatively safe for improving depressive symptoms in bipolar disorder patients.
Area of Science:
- Psychiatry
- Neuroscience
- Pharmacology
Background:
- Bipolar depression treatment is challenging, with mood stabilizers often insufficient and antidepressants risking mania.
- Methylphenidate is effective for unipolar depression and secondary depression.
- Amphetamines can reduce manic behavior, suggesting potential utility for methylphenidate in bipolar depression.
Purpose of the Study:
- To investigate the efficacy and safety of methylphenidate as an adjunctive treatment for bipolar depression.
Main Methods:
- Fourteen subjects with DSM-IV bipolar illness and significant depression (Hamilton Depression Rating Scale [HAM-D] ≥ 15) received methylphenidate.
- Methylphenidate was added to existing mood stabilizer regimens.
- Patients were monitored for 12 weeks.
Main Results:
- Mean HAM-D scores decreased significantly from baseline to last observation carried forward (LOCF) (p=0.019).
- Psychiatric Symptom Assessment Scale (PSAS) scores also showed significant reductions from baseline to LOCF (p=0.007).
- Three participants discontinued due to side effects (anxiety, agitation, hypomania).
Conclusions:
- Methylphenidate appears to be an effective and relatively safe treatment option for bipolar depression.
- Further research with larger, controlled studies is warranted.
Related Concept Videos
01:24Mania and Antimanic Drugs: Overview
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:30Attention-Deficit/Hyperactivity Disorder
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.